Applications of (3R,4S)-1-Benzoyl-4-Phenyl-3-[(Triethylsilyl)Oxy]-2-Azetidinone in Industrial Manufacturing

(3R,4S)-1-Benzoyl-4-Phenyl-3-[(Triethylsilyl)Oxy]-2-Azetidinone is a core chiral intermediate widely adopted by industrial pharmaceutical, fine chemicals, and advanced research manufacturers. Its unique structural properties support several advanced synthesis pathways. Below, we detail key downstream industrial applications, focusing on real-world process integration, regulatory adherence, and typical usage requirements.

1. β-Lactam Antibiotic Synthesis

Large-scale API plants use this chiral azetidinone as a key intermediate in the synthesis of extended-spectrum β-lactam antibiotics. The stereochemistry directly influences the activity profile of third-generation cephalosporins and carbapenems. Production lines integrate this raw material during the crucial condensation phase, controlling impurity levels and chiral purity to meet pharmacopoeial monograph specifications. Manufacturing typically runs under cGMP with full traceability from intermediate to final dosage form.

Industry compliance standards

• USP/NF and Ph. Eur. monographs for β-lactam antibiotics
• WHO GMP guidelines for API production
• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• 21 CFR Part 210/211 for finished pharmaceuticals

Typical usage ratio

• Intermediate utilized at 0.9–1.2 mol equivalent relative to target β-lactam core
• Adjustment based on desired enantiopurity and final product yield

Downstream process integration

• Introduced in the azetidinone ring expansion or acylation step
• Monitoring of chiral integrity via HPLC/UPLC
• In-line quality control for byproduct minimization

Final product types

• Ceftriaxone sodium for injection
• Cefepime hydrochloride
• Meropenem sterile API
• Bulk third- and fourth-generation cephalosporins

2. Chiral Building Block in Custom Peptide Synthesis

Peptide API manufacturers rely on this optically pure azetidinone to introduce β-lactam motifs within modified peptide frameworks. Its triethylsilyloxy group serves as a site-specific protecting function, enabling cleaner deprotection and coupling. Companies producing complex peptide drugs and peptide-based diagnostics employ this intermediate in solid-phase and solution-phase peptide assembly.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• ISO 9001:2015 certification for chemical manufacturing
• US FDA DMF registration for peptide intermediates
• GMP Annex 2 for biological and chemical APIs

Typical usage ratio

• Commonly 1 equivalent relative to modified amino acid residue
• May increase up to 1.3 equivalents to drive complete ring incorporation in low-yielding processes

Downstream process integration

• Added during peptide elongation for β-lactam cyclization
• Protected intermediate introduced into N-terminus linkage
• Supports solid-phase and liquid-phase peptide synthesis

Final product types

• Modified therapeutic peptides with β-lactam scaffold
• Peptide-based imaging agents
• Active pharmaceutical ingredients for orphan drugs
• Synthetic peptide standards

3. Intermediate for Custom Chiral Ligand Production

Catalyst and ligand manufacturers employ this triethylsilyl-protected azetidinone in the design of asymmetric ligands for fine chemical and pharmaceutical catalysis systems. The rigid chiral environment facilitated by the (3R,4S) configuration supports high enantioselectivity in asymmetric hydrogenations and cycloadditions. Integration occurs during backbone assembly prior to deprotection and final functionalization.

Industry compliance standards

• ISO 9001:2015 for fine chemical process management
• REACH registration for commercial intermediate production
• In-house analytical validation to ChP and JIS standards
• Material traceability according to ISO 14001 for environmental management

Typical usage ratio

• Usage at 0.5–1.5 mol per ligand synthesis run
• Adjustment depends on targeted ligand complexity

Downstream process integration

• Inserted at core chiral backbone formation stage
• Subsequent steps: triethylsilyl deprotection, further functional group introduction
• HPLC, NMR monitoring ensures batch consistency

Final product types

• Chiral phosphine and amine ligands
• Asymmetric hydrogenation catalyst precursors
• Custom chelating agents for fine chemical applications
• Pilot-scale and commercial chiral catalysts

4. Advanced Research-Grade API Intermediate

Preclinical research institutions and CROs use this intermediate for synthesis of new β-lactam based scaffolds and potential enzyme inhibitors. The unique combination of benzoyl, phenyl, and triethylsilyloxy groups allows researchers to probe SAR across various β-lactam derivatives. This material’s strict batch traceability supports regulatory filings and data reproducibility for IND-enabling studies.

Industry compliance standards

• GLP (Good Laboratory Practice) for non-clinical studies
• OECD guidelines for toxicological screening compounds
• USP quality verification for research substances
• Internal quality protocols based on ICH Q2(R1) analytical methods validation

Typical usage ratio

• Varies by synthetic target: 0.1–1.0 mol scale batches for research
• Adjusted according to the complexity and number of derivatives in screening sets

Downstream process integration

• Early-stage scaffold construction for lead optimization
• Incorporated in custom route exploration and analog library synthesis
• Crystallization used for chiral purity confirmation

Final product types

• Novel β-lactam scaffolds as potential drug candidates
• Small molecule enzyme inhibitors for academic research
• Proprietary screening compounds for pharmaceutical libraries
• Research-use only intermediates for SAR studies